NCT04835714终止1 期
A Phase I Open-label Dose Escalation Trial of BI 1701963 as Monotherapy and in Combination With BI 3011441 in Patients With KRAS Mutated Advanced or Metastatic Solid Tumours
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 8
- 试验地点
- 4
- 主要终点
- Number of patients with dose-limiting toxicities (DLTs) in the Maximum tolerated dose (MTD) evaluation period in monotherapy (Part A)
研究概览
简要总结
This is a study in adults with advanced cancer (solid tumours including non-small cell lung cancer and colorectal cancer) in whom previous chemotherapy was not successful. People who have a tumour with a KRAS mutation can participate in the study. A KRAS mutation makes cancer grow faster.
The study tests 2 medicines called BI 1701963 and BI 3011441. BI 1701963 and BI 3011441 prevent activation of KRAS.
The purpose of this study is to find out the highest dose of BI 1701963 alone and in combination with BI 3011441 the participants can tolerate. Another purpose is to check whether BI 1701963 in combination with BI 3011441 is able to make tumours shrink.
Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they get tablets of BI 1701963 and capsules of BI 3011441 once daily. The doctors regularly monitor the size of the tumour. Doctors also regularly record any unwanted effects and check participants' health.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
盲法说明
Description to randomisation:
In Part A and Part B no randomisation will be performed. In Part C and Part D randomisation will be performed.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Previously-identified activating Kirsten rat sarcoma viral oncogene homologue (KRAS) mutation in tumour tissue or blood prior to screening. Activating mutations may include but are not limited to: KRAS mutations in expressed region (exon) 2 (G12, G13), exon 3 (A59, Q61) and exon 4 (K117, A146).
- •Provision of archival tumour tissue, if available, to confirm retrospectively KRAS mutation status and for biomarker assessment
- •At least one target lesion that can be measured per Response Evaluation Criteria In Solid Tumours (RECIST) version 1.
- •In patients who only have one target lesion, and a biopsy of the lesion is required, the baseline imaging must be performed at the earliest two weeks after the biopsy.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening
- •Adequate organ function at screening as follows:
- •Absolute neutrophil count (ANC) ≥1.5 x 109/L; hemoglobin ≥9.0 g/dL; platelets ≥100 x 109/L without the use of haematopoietic growth factors or recent transfusion
- •Total bilirubin ≤1.5 times the upper limit of normal (ULN), or ≤4 x ULN for patients who are known to have Gilbert's syndrome.
- •Creatinine ≤1.5 x ULN. If creatinine is >1.5 x ULN, patient is eligible if concurrent glomerular filtration rate (GFR) ≥50 mL/min (measured or calculated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula).
- •Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3 x ULN if no demonstrable liver metastases, or ≤ 5 x ULN if transaminase elevation is attributable to liver metastases.
- •Age ≥18 years of age, or over the legal age of consent as required by local legislation at informed consent.
- •Recovery from any previous therapy related toxicity to Common Terminology Criteria for Adverse Events (CTCAE) Grade ≤1 at Cycle 1 Day 1 (except for alopecia, stable sensory neuropathy must be CTCAE Grade ≤2 and except for amenorrhea/menstruation related disorders of any grade) before the first dose.
- •Signed and dated written informed consent in accordance with Good Clinical Practice (GCP) and local legislation prior to admission to the trial.
- •Further inclusion criteria apply.
排除标准
- •Previous anticancer chemotherapy or anticancer immunotherapy within 3 weeks of the first administration of trial drug. Previous anticancer hormonal treatment within 2 weeks of the first administration of trial drugs.
- •Previous treatment with Rat sarcoma (RAS), Mitogen-activated protein kinase (MAPK) or Son of Sevenless 1 (SOS1) targeting agents
- •Radiotherapy within 4 weeks prior to start of treatment except as follows
- •Palliative radiotherapy to regions other than the chest is allowed up to 2 weeks prior to start of treatment
- •Single dose palliative radiotherapy for symptomatic metastasis within 2 weeks prior to start of treatment may be allowed but must be discussed with the sponsor.
- •Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to start of treatment or planned during the projected course of the trial, e.g. hip replacement.
- •Previous treatment with any investigational agent(s) or targeted treatment within 28 days prior to start of treatment.
- •Known history of hypersensitivity to any of the excipients of BI 1701963 tablets
- •History or presence of cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New-York-Heart-Assocation (NYHA) classification of ≥3, unstable angina or poorly controlled arrhythmia which are considered clinically relevant by the investigator; myocardial infarction within 6 months prior to start of treatment. Uncontrolled hypertension is defined as: Blood pressure (BP) measured in a rested and relaxed condition, where systolic BP ≥140 mmHg, or diastolic BP ≥90 mmHg, with or without medication.
- •Left ventricular ejection fraction (LVEF) <50 %. Further exclusion criteria apply.
研究组 & 干预措施
Part A with Monotherapy dose escalation
Experimental
干预措施: BI 1701963 (Drug)
Part B with Combination therapy dose escalation
Experimental
干预措施: BI 1701963 (Drug)
Part B with Combination therapy dose escalation
Experimental
干预措施: BI 3011441 (Drug)
Part C with Combination therapy dose confirmation
Experimental
干预措施: BI 1701963 (Drug)
Part C with Combination therapy dose confirmation
Experimental
干预措施: BI 3011441 (Drug)
Part D with Combination therapy dose expansion
Experimental
干预措施: BI 1701963 (Drug)
Part D with Combination therapy dose expansion
Experimental
干预措施: BI 3011441 (Drug)
结局指标
主要结局
Number of patients with dose-limiting toxicities (DLTs) in the Maximum tolerated dose (MTD) evaluation period in monotherapy (Part A)
时间窗: Up to 28 days
Objective response (OR) defined as best overall response of confirmed complete response (CR) or confirmed partial response (PR) in combination therapy dose confirmation (Part C)
时间窗: Up to 12 months
Best overall response is defined according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 as assessed by the investigator and will consider all tumour assessments from first administration until disease progression or death (whichever occurs first) or last evaluable tumour assessment before start of subsequent anticancer therapy, loss to follow-up or withdrawal of consent.
Number of patients with dose-limiting toxicities (DLTs) in the Maximum tolerated dose (MTD) evaluation period in combination therapy (Part B)
时间窗: Up to 28 days
Objective response (OR) defined as best overall response of confirmed complete response (CR) or confirmed partial response (PR) in combination therapy dose expansion (Part D)
时间窗: Up to 12 months
Best overall response is defined according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 as assessed by the investigator and will consider all tumour assessments from first administration until disease progression or death (whichever occurs first) or last evaluable tumour assessment before start of subsequent anticancer therapy, loss to follow-up or withdrawal of consent.
次要结局
- Area under the plasma concentration-time curve over the time interval from 0 to the last quantifiable data point (AUC0-tz) of BI 1701963 after the first dose in monotherapy (Part A)(Up to 24 hours)
- Maximum plasma concentration at steady state (Cmax,ss) of BI 1701963 after multiple doses in monotherapy (Part A)(Up to 12 weeks)
- Maximum plasma concentration at steady state (Cmax,ss) of BI 3011441 after multiple doses (Part B only)(Up to 12 weeks)
- Number of patients with Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥3 treatment-related adverse events observed during the on-treatment period in combination therapy dose confirmation (Part C)(Up to 12 months)
- Maximum plasma concentration at steady state (Cmax,ss) of BI 1701963 after multiple doses in combination therapy dose expansion (Part D)(Up to 12 weeks)
- Maximum plasma concentration (Cmax) of BI 3011441 after the first dose in combination therapy dose expansion (Part D)(Up to 24 hours)
- Maximum plasma concentration (Cmax) of BI 1701963 after the first dose in combination therapy (Part B)(Up to 24 hours)
- Area under the concentration-time curve at steady state over the uniform dosing interval τ (AUCτ,ss) of BI 3011441 after multiple doses (Part B only)(Up to 12 weeks)
- Maximum plasma concentration (Cmax) of BI 1701963 after the first dose in monotherapy (Part A)(Up to 24 hours)
- Area under the plasma concentration-time curve over the time interval from 0 to the last quantifiable data point (AUC0-tz) of BI 3011441 after the first dose (Part B only)(Up to 24 hours)
- Area under the plasma concentration-time curve over the time interval from 0 to the last quantifiable data point (AUC0-tz) of BI 1701963 after the first dose in combination therapy (Part B)(Up to 24 hours)
- Maximum plasma concentration at steady state (Cmax,ss) of BI 1701963 after multiple doses in combination therapy (Part B)(Up to 12 weeks)
- Area under the concentration-time curve at steady state over the uniform dosing interval τ (AUCτ,ss) of BI 1701963 after multiple doses in monotherapy (Part A)(Up to 12 weeks)
- Area under the concentration-time curve at steady state over the uniform dosing interval τ (AUCτ,ss) of BI 1701963 after multiple doses in combination therapy (Part B)(Up to 12 weeks)
- Maximum plasma concentration (Cmax) of BI 3011441 after the first dose (Part B only)(Up to 24 hours)
- Number of patients with Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥3 treatment-related adverse events observed during the on-treatment period in combination therapy dose expansion (Part D)(Up to 12 months)
- Area under the concentration-time curve at steady state over the uniform dosing interval τ (AUCτ,ss) of BI 3011441 after multiple doses in combination therapy dose confirmation (Part C)(Up to 12 weeks)
- Area under the concentration-time curve at steady state over the uniform dosing interval τ (AUCτ,ss) of BI 3011441 after multiple doses in combination therapy dose expansion (Part D)(Up to 12 weeks)
- Tumour shrinkage (in millimetres) in combination therapy dose confirmation (Part C)(Up to 12 months)
- Progression-free survival (PFS) rate at 6 months in combination therapy dose confirmation (Part C)(Up to 6 months)
- Maximum plasma concentration (Cmax) of BI 1701963 after the first dose in combination therapy dose confirmation (Part C)(Up to 24 hours)
- Maximum plasma concentration (Cmax) of BI 1701963 after the first dose in combination therapy dose expansion (Part D)(Up to 24 hours)
- Area under the plasma concentration-time curve over the time interval from 0 to the last quantifiable data point (AUC0-tz) of BI 1701963 after the first dose in combination therapy dose confirmation (Part C)(Up to 24 hours)
- Area under the concentration-time curve at steady state over the uniform dosing interval τ (AUCτ,ss) of BI 1701963 after multiple doses in combination therapy dose confirmation (Part C)(Up to 12 weeks)
- Maximum plasma concentration (Cmax) of BI 3011441 after the first dose in combination therapy dose confirmation (Part C)(Up to 24 hours)
- Area under the plasma concentration-time curve over the time interval from 0 to the last quantifiable data point (AUC0-tz) of BI 3011441 after the first dose in combination therapy dose confirmation (Part C)(Up to 24 hours)
- Area under the plasma concentration-time curve over the time interval from 0 to the last quantifiable data point (AUC0-tz) of BI 3011441 after the first dose in combination therapy dose expansion (Part D)(Up to 24 hours)
- Maximum plasma concentration at steady state (Cmax,ss) of BI 3011441 after multiple doses in combination therapy dose confirmation (Part C)(Up to 12 weeks)
- Maximum plasma concentration at steady state (Cmax,ss) of BI 3011441 after multiple doses in combination therapy dose expansion (Part D)(Up to 12 weeks)
- Duration of Objective Response (OR) in combination therapy dose expansion (Part D)(Up to 12 months)
- Area under the plasma concentration-time curve over the time interval from 0 to the last quantifiable data point (AUC0-tz) of BI 1701963 after the first dose in combination therapy dose expansion (Part D)(Up to 24 hours)
- Maximum plasma concentration at steady state (Cmax,ss) of BI 1701963 after multiple doses in combination therapy dose confirmation (Part C)(Up to 12 weeks)
- Area under the concentration-time curve at steady state over the uniform dosing interval τ (AUCτ,ss) of BI 1701963 after multiple doses in combination therapy dose expansion (Part D)(Up to 12 weeks)
- Duration of Objective Response (OR) in combination therapy dose confirmation (Part C)(Up to 12 months)
- Tumour shrinkage (in millimetres) in combination therapy dose expansion (Part D)(Up to 12 months)
- Progression-free survival (PFS) rate at 6 months in combination therapy dose expansion (Part D)(Up to 6 months)
研究者
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)Solid Tumors, KRAS Mutation; SOS1NCT04111458Boehringer Ingelheim71
暂停
1 期
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)Solid TumorsNCT05155332Boehringer Ingelheim190
进行中（未招募）
1 期
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are ToleratedSolid TumorsNCT05327946Boehringer Ingelheim42
已完成
1 期
This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.NeoplasmsCarcinoma, Non-Small-Cell LungNCT03156114Boehringer Ingelheim172
终止
1 期
A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced CancerSolid TumorsNCT05839600Boehringer Ingelheim10